Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma
Autore:
Wilson, AM; Dempsey, OJ; Sims, EJ; Lipworth, BJ;
Indirizzi:
Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY Therapeut, Dundee DD1 9SY, Scotland
Titolo Testata:
CLINICAL AND EXPERIMENTAL ALLERGY
fascicolo: 4, volume: 31, anno: 2001,
pagine: 616 - 624
SICI:
0954-7894(200104)31:4<616:ACOTBA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEUKOTRIENE RECEPTOR ANTAGONIST; EXERCISE-INDUCED BRONCHOCONSTRICTION; EXHALED NITRIC-OXIDE; TO-MODERATE ASTHMA; BRONCHIAL RESPONSIVENESS; FLUTICASONE PROPIONATE; INHALED BUDESONIDE; MILD ASTHMA; INFLAMMATION; AIRWAY;
Keywords:
asthma; allergic rhinitis; corticosteroid; leukotriene antagonist; adenosine monophosphate; bronchial hyperreactivity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Lipworth, BJ Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY undee DD1 9SY, Scotland
Citazione:
A.M. Wilson et al., "A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma", CLIN EXP AL, 31(4), 2001, pp. 616-624

Abstract

Background Allergic rhinitis and asthma commonly coexist and are both mediated by similar inflammatory mechanisms. Leukotriene antagonists may therefore be an alternative to corticosteroid therapy. Objective To compare oral montelukast with inhaled plus intranasal budesonide in patients with seasonal allergic rhinitis and asthma. Patients and methods A single-blind double-dummy placebo-controlled crossover study was performed comparing once daily 10 mg oral montelukast with 400 mug inhaled plus 200 mug intranasal budesonide in 12 patients with allergic rhinitis and asthma: mean (S.E.) age 34.0 years (2.7), forced expiratoryvolume in 1 s (FEV1) 91.2 (3.8)% predicted. Each treatment was for 2 weekswith a 1-week placebo run-in and washout. Measurements were made after each active treatment and placebo for: adenosine monophosphate bronchial challenge, exhaled and nasal nitric oxide. Patients also recorded their domiciliary peak expiratory flow, nasal peak inspiratory flow, asthma and seasonal allergic rhinitis symptoms. Results There were no significant differences between the placebos for anymeasurement. For adenosine monophosphate PC20, geometric mean fold differences (95% confidence interval (CI) for difference) were 6.4 (2.2-18.6) for placebo vs. budesonide, 2.9 (1.0-8.4) for placebo vs. montelukast, and 2.1 (1.1-4.5) for budesonide vs. montelukast. For exhaled nitric oxide (p.p.b.)there was significant (P < 0.05) suppression with both montelukast (10.9) and budesonide (10.1) compared with placebo (18.8). For nasal nitric oxide and nasal peak flow there were only significant differences with budesonidecompared with placebo. Both treatments reduced total seasonal allergic rhinitis symptoms but only budesonide had a significant effect on nasal symptoms. Conclusion Once-daily inhaled plus intranasal budesonide and once daily montelukast showed comparable efficacy on lower airway, but only the budesonide had significant efficacy on upper airway inflammatory markers. Both treatments significantly reduced allergic rhinitis symptoms.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/02/20 alle ore 03:00:46